Tag Archives: MEQ

PR Newswire

QYNAPSE (France) and TRUE POSITIVE MEDICAL DEVICES (Canada) are partnering to provide the most advanced AI platform for brain diseases

Leave a comment

Strategic partnership in brain imaging and AI

PARIS, MONTREAL, and QUEBEC CITY, Oct. 13, 2020 —

  • Acquisition of TRUE POSITIVE MEDICAL DEVICES by QYNAPSE
  • A strategic collaboration that covers 15 patents, including 9 issued in the U.S. and Canada
  • A unique technology alliance to improve clinical trials performance and personalize brain diseases management

QYNAPSE SAS, a French medical technology company, today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off from the universities of McGill and Laval. The objective of this strategic collaboration is to combine TPMD’s technologies, patents and expertise with Qynapse’s know-how and product line – and thus form the most advanced artificial intelligence (AI) platform in the field of imaging of brain diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis.

The QyScore application
The QyScore application

Over the past fifteen years, the founders of TPMD, Prof. Louis Collins (McGill University, Montreal, Canada) and Prof. Simon Duchesne (Université Laval, Quebec City, Canada) have established one of the most impressive scientific and technological asset bases in brain imaging and AI applied to this field, supported by more than 500 publications and scientific communications. These technologies are already being used in Canada by leading research consortia and private international players in studies specifically related to neurodegeneration, such as Alzheimer’s disease.

QYNAPSE is already marketing its first QyScore® medical device to clinical centers in Europe and the United States. Its platform is also used in clinical trials involving dozens of centers worldwide. The collaboration with TPMD will allow QYNAPSE to extend the applications of its QyScore® software to other brain diseases such as stroke, epilepsy, autism, schizophrenia, and head trauma – and also to develop new software to predict clinical progression for individual patients and optimize enrollment in clinical trials.

QYNAPSE’s acquisition of TPMD covers 15 patents, including 9 issued in the United States and Canada, grouped into nine technological asset families. The founders of TPMD will join QYNAPSE’s scientific board, setting the stage for a long-term collaboration.

According to Prof. Louis Collins: "QYNAPSE is a very promising partner for TPMD and both McGill and Laval universities, which will allow us to accelerate the regulatory approval and marketing of the technologies we have developed in recent years". Prof. Duchesne adds, "Indeed, with QYNAPSE we will have access to a partner that is already well established in the medical field. We look forward to providing clinicians with the tools they need to improve the accuracy of their diagnosis, facilitate prognosis and guide treatment for diseases such as dementias and cerebrovascular diseases."

"We are delighted to partner with two of the world’s leading experts in brain imaging, and to expand our scientific and clinical collaborations with two major centers of excellence in this field." said Olivier Courrèges, CEO of QYNAPSE. "This collaboration will create a unique technological structure, strengthening our ability to deploy powerful tools to address two major challenges: clinical trial performance and personalized management of brain diseases, which affect more than one in six people worldwide."

Once finalized, TPMD will be integrated into QYNAPSE CANADA Inc. and TPMD’s scientific and commercial partnership contracts will be operated by this new entity.

About QYNAPSE

Founded in 2015, QYNAPSE is a French medical technology company, a spin-off from the CATI consortium of neuroimaging research laboratories. The company develops and markets solutions utilizing the potential of quantitative imaging and artificial intelligence to optimize diagnosis, prognosis and monitoring of patients with neurological diseases.
QYNAPSE is headquartered in Paris (France) and in Boston (USA).
www.qynapse.com 
www.qynapse.com/qyscore-software/ 

About TRUE POSITIVE MEDICAL DEVICES (TPMD)

Founded in 2011, TRUE POSITIVE MEDICAL DEVICE Inc. is a spin-off from the work of Prof. Simon Duchesne at the CERVO Brain Research Center and Université Laval and Prof. Louis Collins at the Montreal Neurological Institute and McGill University. The company designs, validates and operates a brain image processing platform to aid in the diagnosis and prognosis of neurological and psychiatric diseases.
TPMD is based in Montreal and Quebec City (QC, Canada).
www.truepositivemd.com  

Logo – https://techent.tv/wp-content/uploads/2020/10/qynapse-france-and-true-positive-medical-devices-canada-are-partnering-to-provide-the-most-advanced-ai-platform-for-brain-diseases-2.jpg
Photo – https://techent.tv/wp-content/uploads/2020/10/qynapse-france-and-true-positive-medical-devices-canada-are-partnering-to-provide-the-most-advanced-ai-platform-for-brain-diseases.jpg

Media Contact
Ysé Sallé de Chou
Qynapse
ysalledechou@qynapse.com

PR Newswire

Life-changing medical innovations that makes the impossible possible

Leave a comment

STOCKHOLM, Oct. 8, 2020 — Medical wire that stops the trembling caused by Parkinson’s disease. Precision tools that can manufacture tailored prosthetic limbs durable and flexible enough to race down the slopes. And 3D-printing technologies that can create scull and spinal implants in just a few hours. With new and improved technology, the potential for helping people who suffers from physical disabilities have never been better.

The technological advancements within the medical sector are almost hard to grasp. At global engineering group Sandvik, one of the fastest growing segments today is Medical, where the company develops products and components that are essential in solutions that change people’s lives for the better.

In a series of films, Sandvik is celebrating some truly inspirational people that have been helped to live a normal life again after using advanced medical innovations and solutions. Click here to see them: home.sandvik/life-changing-innovations

"Our products in the medical field are rarely seen since they are often a part of the manufacturing process or imbedded in another device. Now we want to highlight the fascinating work happening within the medical sector and encourage more people and partners to look into some of these solutions and be inspired to advance the world of medical innovations even further," says Jessica Alm, Executive Vice President and Head of Communications at Sandvik Group.

Examples of disabilities where Sandvik’s innovations are a part of the life changing solutions are Diabetes, Parkinson’s disease, Hearing loss and physical injuries caused by accidents. Sandvik’s super thin medical wires, machining tools and cutting-edge knowledge within 3D-printing are important stepstones on the route back to a life with minimum impact from the disability.

But don’t take Sandvik’s word for it. Watch the in-depth films, starring persons that have experienced the emotional roller-coaster that comes with living with a disability, and struggling to find a way back to an everyday life.

For more information, contact: Martin Blomgren, Press and Media Relations Manager, email: martin.blomgren@sandvik.com phone: +46 70 577 0549

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

https://mb.cision.com/Main/208/3212624/1316650.pdf

Life-changing medical innovations that makes the impossible possible

 

PR Newswire

Smartphone-based Solutions Boost the Global Infectious Disease Point-of-Care Testing Market at an Explosive CAGR of 70.2% in 2020

Leave a comment

Digital POCT platforms will enable diagnostic testing beyond the clinic, transforming how assay results are gathered and analyzed, finds Frost & Sullivan

SANTA CLARA, California, Oct. 2, 2020 — Frost & Sullivan’s recent analysis, Smartphone-based Solutions Spur the Global Infectious Disease Point-of-Care Testing Market, Forecast to 2024, finds that the outbreak of the COVID-19 pandemic has transformed the infectious disease point-of-care testing (POCT) market. The emergence of cost-effective lab-on-a-chip and smartphone-based POCTs, alongside increasing reliance on less-invasive testing methodologies, will propel the POCT market. Globally, the infectious disease POCT market is estimated to witness more than a three-fold growth, reaching $26.4 billion by 2024 from $7.9 billion in 2019, up at a compound annual growth rate (CAGR) of 27.3%.

Smartphone-based Solutions Boost the Global Infectious Disease Point-of-Care Testing Market at an Explosive CAGR of 70.2% in 2020
Smartphone-based Solutions Boost the Global Infectious Disease Point-of-Care Testing Market at an Explosive CAGR of 70.2% in 2020

For further information on this analysis, please visit: http://frost.ly/4l1.

"The POCT instrument selection process should involve close collaboration with supply and clinical engineering departments to incorporate their input and feedback," said Amartya Bose, Healthcare Industry Analyst at Frost & Sullivan. "This is a key consideration when the POCT committee reviews all options and makes an informed decision. Hospitals/labs/pharmacies should select regional vendors for device procurement and services. This will reduce the procurement lead time and ensure devices are managed for quality assurance, timely calibrations, and interpretation of results."

Nitin Naik, Life Sciences Vice President at Frost & Sullivan, added: "The application of artificial intelligence (AI) and machine learning (ML) is a key growth opportunity for manufacturers to enhance their product portfolios. By leveraging these platforms, POCT assay menus can be expanded for different patient groups by simply iterating the product development cycle. U.S. healthcare providers are also leveraging digital POCT along with virtual assistants to screen and triage asymptomatic patients."

To capitalize on growth opportunities in the current and post-COVID-19 situation, POCT market participants should focus on the following solutions:

  • Multiplexed POCT: Integrate sample preparation and analysis within one device to offer more advantages in a competitive environment.
  • COVID-19 POCT: Develop accurate serology tests and mHealth-based diagnostics, as they will play a critical role in determining the disease’s full scope, combating the pandemic.
  • Digital POCT: Adopt cloud technologies as an integral part of device development to reduce the footprint and cost of POCT devices.
  • Millennials and sexually transmitted infections (STIs): Produce HIV/syphilis dual tests as evidence suggests a two- to five-fold increased risk of acquiring HIV if exposed to it when syphilis is present.

Smartphone-based Solutions Spur the Global Infectious Disease Point-of-Care Testing Market, Forecast to 2024 is the latest addition to Frost & Sullivan’s Healthcare research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Smartphone-based Solutions Spur the Global Infectious Disease Point-of-Care Testing Market, Forecast to 2024
K4C6

Contact:
Mariana Fernandez
Corporate Communications
P: +1 210 348 10 12
E: Mariana.Fernandez@frost.com
http://ww2.frost.com

Photo – https://techent.tv/wp-content/uploads/2020/10/smartphone-based-solutions-boost-the-global-infectious-disease-point-of-care-testing-market-at-an-explosive-cagr-of-70-2-in-2020.jpg

 

Related Links :

Frost New Home page v2

PR Newswire

Turning AI onto itself: AI algorithm detects when medical images will be difficult for radiologists or AI to make an effective diagnosis

Leave a comment

SAN FRANCISCO, Sept. 30, 2020 — A new AI algorithm can identify when medical images are likely to be difficult for either a radiologist or AI to make an effective diagnosis. The algorithm can potentially be used to triage medical scans and highlight cases that warrant further in-depth clinical evaluation or additional tests to support a definitive clinical diagnosis.

Radiologist diagnosing x-ray scan
Radiologist diagnosing x-ray scan

The algorithm, called UDC by AI healthcare company Presagen, was originally designed to automatically detect errors in medical data, particularly data that cannot be reliably verified by experts.

When applied to images of x-rays to detect pneumonia, errors by radiologists were rare when the x-ray images had clear features. However, UDC found the diagnosis (or label) for several x-ray images to be neither correct nor an error. Verification of these images by an independent radiologist also agreed that they were indeed difficult images to diagnose, with their independent assessment often disagreeing with the original diagnosis provided in the public dataset. Similarly, AI that was trained to diagnose pneumonia also found the assessment difficult for these images.

Removal of poor-quality (difficult) images identified by UDC from the training dataset improved AI accuracy for diagnosing pneumonia in x-rays images by over 10% as measured on a hold out blind test set, and the AI was shown to be more scalable (generalizable). The accuracy also exceeded benchmarks set by the current literature for that public dataset.

The AI Scientist that led the project, Dr Milad Dakka, said "Our results suggest these poor-quality images are uninformative, counter-productive or confusing when used in training AI. The ability to identify when new images are poor-quality is important to prevent an inaccurate AI clinical assessment, but also to alert the radiologist when the scan is likely to be difficult to diagnose or when a new scan should be taken."

Presagen Co-Founder and Chief Strategy Officer, Dr Don Perugini said "Many AI practitioners believe that AI performance and scalability can be solved with more data. This is not true, and we call it the AI data fallacy. Even 1% poor-quality data can impact the performance of the AI. Building accurate and scalable AI is about using the right data."

Presagen has recently developed a range of patent-pending AI technologies that drive a fundamental paradigm shift in developing commercially scalable AI products for real-world problems, which apply beyond healthcare and to AI more generally.

Dr Michelle Perugini said "We are excited to present to the world the suite of technologies, which we believe advance the field of AI. These technologies will allow Presagen to build scalable ‘out of the box’ AI products that are more commercially viable and technically superior, and thus market dominating. This is vital in Presagen’s journey to become world-leaders in AI Enhanced Healthcare and a dominant player in the AI-in-Femtech market globally. More importantly, we see it as an opportunity to change, lead, and dominate the AI industry."

 

Related Links :

https://www.presagen.com/

PR Newswire

Infosys to Acquire Product Design and Development firm, Kaleidoscope Innovation

Leave a comment

Expands engineering services portfolio by strengthening presence in Medical devices, Consumer and Industrial markets across US

BENGALURU, India and CINCINNATI, Sept. 4, 2020 — Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced a definitive agreement to acquire Kaleidoscope Innovation, a full-spectrum product design, development and insights firm innovating across medical, consumer and industrial markets, bolstering capabilities in the design of smart products. This acquisition demonstrates Infosys’ commitment to innovate for its clients, and make a meaningful impact on human lives by combining cutting-edge technologies and experiences to revolutionize patient care, treatment, diagnostics and consumer health across the world.

Kaleidoscope Innovation brings to Infosys a diverse talent pool with extensive knowledge of design and engineering. The company leverages a deep understanding of clinical environments, strong product development capabilities across domains, and a consultancy-style approach addressing human factors, product design, UI/UX design, research & insight, development and visualization. It serves a marquee and diversified customer base with state of the art, in-house labs, 3D design environments and customer experience centers. Kaleidoscope designs microsurgical instruments, devices used in minimally invasive surgery, drug delivery devices for ophthalmic therapies and user-centric wearables. It also offers usability testing in support of regulatory submissions, including the delivery mechanism for aortic stents.

Ravi Kumar, President, Infosys, said, "This acquisition further strengthens our digital offerings at the intersection of new software technologies and medical devices – a sector that is expected to witness significant investments and consumerization in the post-COVID era. Our clients will benefit from the combination of Kaleidoscope’s strong upstream offerings of product innovation and design, and Infosys’ stack of product engineering, validation and commercialisation services at a global scale. We are excited to welcome Kaleidoscope Innovation and its leadership team into the Infosys family, as part of Infosys Engineering Services portfolio."

Nitesh Bansal, SVP & Global Head of Engineering, Infosys, said, "Device engineering for both the consumer and medical industries has been a critical success parameter for our clients. The addition of upstream concept design and human factors engineering, through this acquisition not only provides us end-to-end capability, but also creates an engagement engine dedicated towards innovation and growth in this sector."

Matt Kornau, CEO & Co-Founder, Kaleidoscope Innovation said, "We are enthusiastic about our exciting new partnership with Infosys. It allows us to scale quickly and bring expanded offerings in AI, Analytics, and Digital Infrastructure to our clients. Kaleidoscope has always valued the ability to enhance people’s lives and their outcomes through innovation. We feel Infosys shares these same values and will open new avenues for our client partners, and our staff, to pursue larger opportunities together.  We will remain dedicated to serving as good partners to other companies, large and small, as we continue to meet our mission."

Bill Taylor, Co-Founder, Kaleidoscope Innovation added, "Infosys provides an exciting platform for us to extend our relationship with our Business Partners to address the productization of solutions they have been asking us to deliver. Having the technical prowess and bandwidth to offer solutions that address manufacturability and lifecycle management will benefit all parties. We can now offer them the scale needed for both front end innovation and back end implementation and sustainability"

The acquisition is expected to close during the second quarter of fiscal 2021, subject to customary closing conditions.

About Kaleidoscope Innovation

Kaleidoscope Innovation is a full-service product development firm innovating across medical, consumer and industrial markets. For over 30 years, clients have partnered with Kaleidoscope to improve the human experience. Kaleidoscope offers both consultancy-style and onsite services, across a full breadth of disciplines to meet their client’s needs where needed, including insights & human factors, medical affairs, industrial design & user experience, engineering, visualization and software development. For more information about Kaleidoscope Innovation, please visit www.kascope.com

About Infosys

Infosys is a global leader in next-generation digital services and consulting. We enable clients in 46 countries to navigate their digital transformation. With nearly four decades of experience in managing the systems and workings of global enterprises, we expertly steer our clients through their digital journey. We do it by enabling the enterprise with an AI-powered core that helps prioritize the execution of change. We also empower the business with agile digital at scale to deliver unprecedented levels of performance and customer delight. Our always-on learning agenda drives their continuous improvement through building and transferring digital skills, expertise, and ideas from our innovation ecosystem.

Visit www.infosys.com to see how Infosys (NYSE: INFY) can help your enterprise navigate your next.

Safe Harbor

Certain statements in this release concerning our future growth prospects, financial expectations and plans for navigating the COVID-19 impact on our employees, clients and stakeholders are forward-looking statements intended to qualify for the ‘safe harbor’ under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding COVID-19 and the effects of government and other measures seeking to contain its spread, risks related to an economic downturn or recession in India, the United States and other countries around the world, changes in political, business, and economic conditions, fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our industry and the outcome of pending litigation and government investigation. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2020. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company’s filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.

Logo: https://mma.prnasia.com/media2/633365/Infosys_Logo.jpg?p=medium600

PR Newswire

Jvion Lauded by Frost & Sullivan for Improving Patient Outcomes Using Its Clinical-AI CORE™ Intelligence Platform

Leave a comment

Jvion’s prescriptive analytics approach identifies undetected risk and modifiable risk trajectories followed by recommendations for remedial actions

SANTA CLARA, California, Sept. 1, 2020 — Based on its recent analysis of the North American prescriptive analytics market, Frost & Sullivan recognizes Jvion, Inc. with the 2020 North American Technology Innovation Leadership Award for its clinical-AI Care Optimization and Recommendation Enhancement (CORE™) technology. It is a scalable, secure intelligence repository that aggregates structured as well as unstructured data and augments that information with clinical, socioeconomic, and experiential data on 30 million individuals to draw meaningful correlations and inferences. To date, Jvion’s clinical AI has helped more than 300 hospitals, payers, and pharmacy managers achieve 30 percent reductions in preventable adverse incidents, which translate to annual savings of more than $6.3 million.

2020 North American Prescriptive Analytics Technology Innovation Leadership Award
2020 North American Prescriptive Analytics Technology Innovation Leadership Award

"The CORE™ identifies health and financial risk trajectories that can be modified, delivers prioritized insights to the care teams and coordinators engaging patients, and makes recommendations to improve outcomes. As a prescriptive analytics solution, it can proactively mitigate preventable harm that could otherwise lead to hospital readmissions, serious conditions, or accelerated health deterioration," said Cecilia Van Cauwenberghe, Industry Principal. "With this first-in-class AI platform, Jvion evolved from a provider of simple predictive analytics and machine learning solutions to a technology leader that can help identify potentially high-risk patients and suggest specific remedial action."

The solution leverages a combination of Eigen-based mathematics, datasets from over 30 million patients, and a software platform to promptly act upon 50+ preventable clinical events, covering behavioral health, hospital acquired conditions, chronic conditions, hospice/palliative care, and medication adherence. Additionally, it can identify avoidable cost events including uncompensated care and help customers work with their patient population to identify the right financial assistance. Importantly, the CORE™ does not require the creation of new models or perfect datasets. The underlying AI capability assesses 4,500 clinical and non-clinical risk factors for every patient and a quadrillion risk calculations through 170,000 self-learning Eigen Spheres clusters in real-time.

Frequently used enterprise data warehouse or data lake models demand considerable resources just to deliver a retrospective view of the patient’s health risk. Similarly, scoring methods such as LACE and BRADEN do not provide enough granularity or patient specificity to determine all the factors impacting the patient’s health. Jvion’s CORE™, on the other hand, boasts patient specificity, high effectiveness (seven times more effective than popular scoring methods), patient rendering (up to 365 days view into the future), successful use of even incomplete and unstructured datasets, and the fastest speed to value. Each of these benefits helps deliver effective, personalized patient care.

"As a result of its patient-centric approach to understanding vulnerability and risk, Jvion was able to pivot quickly during a pandemic to launch its COVID Response Suite, which delivers lists of individuals most vulnerable to severe illness. These insights enable proactive and targeted outreach to individuals that need to take more aggressive precautions," noted Cauwenberghe. "The relevance of its solutions, along with its patient-focused technology development efforts, has positioned Jvion for accelerated growth."

"Jvion is honored to be recognized for executing on its mission of preventing avoidable harm whether categorized as a health or financial event for our customers," said Jay Deady, CEO of Jvion. "Our team is constantly innovating to ensure our prescriptive AI approach is relevant to the changing dynamics of the healthcare industry."

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies that deliver significant customer value.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Harley Gadomski
P: 12104778469
E: harley.gadomski@frost.com

About Jvion, Inc.

Jvion, a leader in clinical artificial intelligence, enables providers, payers and other healthcare entities to identify and prevent avoidable patient harm, utilization and costs. An industry first, the Jvion CORE™ goes beyond predictive analytics and machine learning to identify patients on a trajectory to becoming high-risk. Jvion then determines the interventions that will more effectively reduce risk and enable clinical and operational action. The CORE accelerates time to value by leveraging established patient-level intelligence to drive engagement across healthcare organizations, populations, and individuals. To date, the Jvion CORE has been deployed across hundreds of clients and resulted in millions saved. For more information, visit http://www.jvion.com.

Media Contact:

Anya Nelson
Scratch Marketing + Media for Jvion
anyan@scratchmm.com 
617.817.6559

 

Related Links :

Frost New Home page v2

PR Newswire

G-ray Switzerland announces new CEO, closes successful funding round

Leave a comment

NEUCHÂTEL, Switzerland, Aug. 31, 2020 — G-ray Switzerland, the medical imaging and industrial diagnosis start-up founded in 2014, has announced the appointment of Luis Pallares as Chief Executive Officer, as the company embarks on an accelerated growth drive and completes a successful funding round.

Mr Pallares is focused on leading the transformation of G-ray’s business development efforts following the company’s development of a disruptive and patented state of the art technology to bring safer, cheaper and better vision into imaging for medical and industrial diagnosis.

Mr Pallares joins G-ray with a wealth of entrepreneurial and start-up experience, having founded Spain’s first streaming service, Addhoc Streaming, Spanish-speaking health related content site Vivir Mejor, and Spain’s leading digital strategy firm, Nennisiwok.

Most recently Mr Pallares’ deep experience in technology development, artificial intelligence and digital advertising led him found Plyzer Technologies, a global leader of price comparison technology matched with business analytics and intelligence based on artificial intelligence.

The appointment coincides with the news that G-ray has also raised a further CHF 2.6 millions, enabling it close out its successful Series A funding round at CHF 28 million.

Luis Pallares, Chief Executive Officer of G-ray, said: "G-ray has already proven to be a positive disruptive force within the technology industry and I relish the opportunity to help deliver tangible progress by bringing improvements in imaging into medical and industrial diagnosis."

Mr Yves Claude Aubert, Chairman of G-ray Switzerland, said: "Our technology has already started to disrupt the multi-billion particle detection imaging markets, based on our proprietary and transformative unique detector architecture. As artificial intelligence impacts the traditional X ray detector market, Luis is the perfect choice to lead G-ray forward into a new phase of growth and to capture these opportunities.

About G-ray Switzerland

Founded in 2014 in Neuchâtel, G-ray Switzerland SA has filed a number of revolutionary patents in the fields of radiographic imaging and new semiconductor assembly techniques. The rapidly expanding company has developed core skills in monolithic detectors with integrated high-resolution CMOS circuits. These innovations cover a wide range of sectors, including automotive, aerospace and medicine. www.g-ray.ch

 

 

Related Links :

http://www.g-ray.ch

PR Newswire

Dymax Asia Pacific Pte Ltd Receives the Singapore SME 1000 & SME 1000 Award and Winner of D&B Business Eminence Award

Leave a comment

TORRINGTON, Conn., Aug. 14, 2020 — Dymax Corporation, leading manufacturer of rapid light-curing materials and equipment, is pleased to announce that its Singapore subsidiary, Dymax Asia Pacific Pte Ltd., has received the Singapore 1000 & Singapore SME 1000 award in its annual ranking of best companies in 2020. And it has been awarded one of the winners of the Dun & Bradstreet Business Eminence Award.

Dymax Asia Pacific Pte Ltd. SME Certificate
Dymax Asia Pacific Pte Ltd. SME Certificate

The Singapore 1000 Family of Rankings (Singapore 1000 & Singapore SME 1000) is the prestigious guide that ranks the nation’s top companies annually. For over 30 years, they have been profiling the success of businesses based on financial indicators such as revenue, net profit, return on equity, and overseas revenue. Taking into consideration all companies and requiring no paid nominations, the Singapore 1000 analyzes over 70,000 audited financials each year to arrive at the top 1,000 corporations and SMEs in Singapore. The rankings are shared publicly and distributed to government sectors, embassies, trade organizations, banks, universities, and libraries.

Nominees of the D&B Business Eminence Award receive this distinguished recognition for their achievements as an entrepreneurial business that has contributed to Singapore’s business landscape over the past several years. The assessment of candidates and selection process is based on Dun & Bradstreet’s proprietary financial model that recognizes top performing businesses and helps raise their international profile. The D&B D-U-N-S Registered Seal resonates with customers, suppliers, and business partners.

Dun & Bradstreet has the world’s largest commercial database, with over 240 million company records derived from 30,000 data sources. Some of the largest, most successful technology and service companies in the world embed Dun & Bradstreet data within their offerings. 

Dymax Asia Pacific Pte Ltd. joined in the ranks of this prestigious group being recognized for their abilities and contributions. The company looks forward to an exciting journey as it continually strives to achieve business excellence around the world.

About Dymax Corporation

Dymax Corporation develops innovative rapid and light-curable materials, dispense equipment, and UV/LED light-curing systems. The company’s adhesives, coatings, and equipment are perfectly matched to work seamlessly with each other, providing design engineers with tools to dramatically improve manufacturing efficiencies. Major markets include aerospace and defense; medical device; and consumer and automotive electronics.

For additional information on Dymax, visit www.dymax.com or contact us at info@dymax.com or +65-67522887.

Photo – https://photos.prnasia.com/prnh/20200814/2885951-1?lang=0

Related Links :

http://www.dymax.com

PR Newswire

Global Healthcare Interoperability Market to Witness Nearly Two-fold Growth by 2024

Leave a comment

Data interoperability and data analytics are key contributors to global market revenue for healthcare interoperability, says Frost & Sullivan

SANTA CLARA, California, July 27, 2020 — Frost & Sullivan’s recent analysis, Global Healthcare Interoperability Market, Forecast to 2024, contends that interoperability has become a critical consideration for all health IT (HIT) applications. Countries where HIT interoperability standards are equally important and regulated are projected to drive the market, registering near-double-digit growth. The buoyant market for global healthcare interoperability is expected to grow at a compound annual growth rate (CAGR) of 13.8%, reaching $7.96 billion by 2024 from $4.17 billion in 2019.

Global Healthcare Interoperability Market to Witness Nearly Two-fold Growth by 2024
Global Healthcare Interoperability Market to Witness Nearly Two-fold Growth by 2024

For further information on this analysis, please visit: http://frost.ly/49u.

“With the advent of innovative delivery models and shifting focus on value-based care, the demand for interoperable systems will continue to grow,” said Koustav Chatterjee, Transformational Health Principal Analyst at Frost & Sullivan. “Additionally, the ability to achieve medical device connectivity across the care continuum will be critical. Real-time integration of accurate patient-generated data from connected apps and systems into a central command center platform that uses cognitive algorithms to automate care coordination and personalize intervention will be a key competitive advantage during and post-COVID-19.”

Chatterjee added: “From product segment perspectives, data interoperability and data analytics will primarily dominate the global healthcare data interoperability market. Both of these solution segments are expected to contribute more than 90% of the global market revenue throughout the study period. Further, application program interface (API) integration is the third-most important solution segment contributing to global market revenue, followed by data cleansing, data integration, and application integration.”

Globally, major government agencies are mandating healthcare stakeholders to comply with national healthcare data interoperability standards. This is resulting in higher adoption of HIT applications, thereby presenting immense growth opportunities for vendors involved in healthcare interoperability, including:

  • API Management: Vendors are encouraged to create API partnership platforms to achieve cross-continuum connectivity.
  • Data Management: Cloud or on-premise data centers comprise actionable healthcare intelligence, indicative of a past pattern of diseases, payment frauds, and operational inefficiencies.
  • Electronic Medical Record (EMR) Partnerships: Build the EMR interoperability consulting services business line.
  • Medical Device Partnerships: Utilize real-time assessment of patient-generated data by care episodes and patient population.
  • Health Information Exchange: Develop a central infrastructure to enable the delivery of actionable health data.

Global Healthcare Interoperability Market, Forecast to 2024, is the latest addition to Frost & Sullivan’s Transformational Health research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Global Healthcare Interoperability Market, 2019–2024

K418

Contact:
Mariana Fernandez
Corporate Communications
P: +1 (210) 348.1012
E: mariana.fernandez@frost.com 
https://www.frost.com

Photo – https://mma.prnasia.com/media2/1219817/interoperability_healthcare.jpg?p=medium600

Related Links :

http://www.frost.com

PR Newswire

FUJIFILM Sonosite Launches New Point-Of-Care Ultrasound System With Adaptable Form Factor, Embedded Workflow, And The Most Advanced Image Clarity Sonosite Has Ever Offered

Leave a comment

BROOKVALE, New South Wales, July 24, 2020 — FUJIFILM Sonosite, Inc., specialists in developing cutting-edge point-of-care ultrasound (POCUS) solutions, and part of the larger Fujifilm Healthcare portfolio, has announced the launch of the new Sonosite PX ultrasound system. Sonosite PX is the next generation in Sonosite POCUS, with the most advanced image clarity ever seen in a Sonosite system, a suite of workflow efficiency features, and an adaptable form factor. 

"Every aspect of Sonosite PX was designed specifically for the clinicians on the front lines of medicine. We designed Sonosite PX as a tool to help clinicians in all fields of medicine to treat patients more effectively where it matters most – at the point of care." said Rich Fabian, President and Chief Operating Officer of FUJIFILM Sonosite, Inc. "To optimize clinician ergonomics and improve efficiency, the system has an innovative and adaptable work surface that can be used in a horizontal or vertical position based on the situational needs of the exam. The exceptional image clarity is the result of a new proprietary imaging technology – seeing anatomy more clearly with Sonosite PX provides an unparalleled level of confidence for diagnostic and procedural applications."

As with all Sonosite POCUS systems, Sonosite PX is built to the legendary durability, reliability, and ease of use standards that clinicians around the world depend upon. The ultrasound system and the new family of transducers are drop-tested to one meter and the work surface is sealed to the edge for simplified cleaning and disinfection.  When mounted on the specialized stand, Sonosite PX has an adaptable work surface position for optimal clinician ergonomics while a small footprint and adjustable height allows for closer bedside access. Information essential to completing an exam including patient information, reports, and worksheets, is intuitively placed in one location, saving clinicians time and effort when navigating the ultrasound system user interface.

Diku Mandavia, MD, FACEP, FRCPC, Senior Vice President and Chief Medical Officer of FUJIFILM Sonosite, Inc. explained, "Clinicians are continually expanding their use of ultrasound. With Sonosite PX, they can use one ultrasound system for different workflows because it adapts to fit their diverse needs." The Sonosite PX user interface is simplified to show most-used controls, calculations, and annotations. Dr. Mandavia continued, "The system has two cardiac options that allow clinicians to choose between gathering targeted information about the heart to determine overall patient well-being, or investigate specific cardiac conditions with more comprehensive calculations that provide detailed analysis of the structure and function of the heart. This allows clinicians to select the cardiac exam type that best fits their individual workflow needs. Furthermore in keeping with our commitment to education, we have greatly expanded our 3D animation educational videos which are very important to new users. Sonosite PX has more than 100 onboard scan-along education tutorials; the most expansive library in any point-of-care system."

Recognizing the importance of efficient documentation to the electronic health record (EHR), Sonosite PX has been designed for onboard documentation of ultrasound findings at the bedside. Sonosite PX integrates seamlessly with the company’s Sonosite Synchronicity solution, a workflow manager for POCUS that supports seamless credentialing, quality assurance, and billing across departments and institutions.

Learn more about Sonosite PX by contacting your Sonosite sales representative, or visit https://showcase.sonosite.com/au.

About Fujifilm Sonosite

FUJIFILM Sonosite, Inc. is the innovator in bedside and point-of-care ultrasound, and an industry leader in ultra high-frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by a global distribution network in over 100 countries. Sonosite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, please visit www.sonosite.com.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

Logo – https://techent.tv/wp-content/uploads/2020/07/fujifilm-sonosite-launches-new-point-of-care-ultrasound-system-with-adaptable-form-factor-embedded-workflow-and-the-most-advanced-image-clarity-sonosite-has-ever-offered.jpg

 

Related Links :

https://www.sonosite.com